KLOKKARSTUA, Norway, Aug. 4, 2021 /PRNewswire/ — Mel-Mont Medical, a boutique medical device and technology company dedicated to improving women’s health through the use of its DNA and mRNA patented self-sampling screening kit, Mia by XytoTest®, receives clinical validation as being equally effective to clinician-collected sampling. “Current estimates indicate that every year 569,847 women are… Continue reading Mel-Mont Medical announces the validation of its patented self-sampling technology, Mía by XytoTest®, for molecular screening using HPV-DNA and 7-Type mRNA E6/E7.
Category: Announcement
Self-collected versus clinician-collected cervical samples for the detection of HPV infections by 14-type DNA and 7-type mRNA tests
C. E. Aranda Flores , G. Gomez Gutierrez, J. M. Ortiz Leon, D. Cruz Rodriguez and S. W. Sørbye Abstract Background: HPV self-sampling has been widely supported by the scientific community following a strong body of literature on the subject. Self-sampling is important in cervical cancer screening as it has been shown to improve participation.… Continue reading Self-collected versus clinician-collected cervical samples for the detection of HPV infections by 14-type DNA and 7-type mRNA tests
Mel-Mont Medical, LLC announces the development of Mía by XytoTest®
Mel-Mont Medical, LLC announces the development of Mía by XytoTest® MEXICO CITY, May 17, 2017 /PRNewswire/ — Mía by XytoTest® is a preventive comprehensive diagnostic system developed and patented by the American company, Mel-Mont Medical, LLC founded in 2014 by Frank Meléndez, MSc. and Liliana Montes, MSc. both medical device developers. This innovative system includes a medical device that… Continue reading Mel-Mont Medical, LLC announces the development of Mía by XytoTest®
